{
  "cache_date": "2025-08-01T11:08:18.945394",
  "data": [
    {
      "created": "2025-08-01T07:31:06.674622+00:00",
      "modified": "2025-08-01T07:31:07.145029+00:00",
      "id": 16673810,
      "conceptrecid": "16673809",
      "doi": "10.3897/pharmacia.72.e155983",
      "doi_url": "https://doi.org/10.3897/pharmacia.72.e155983",
      "metadata": {
        "title": "Optimizing formulation and development of amlodipine-indapamide bilayer film-coated tablets with in vitro dissolution equivalence to a reference drug",
        "doi": "10.3897/pharmacia.72.e155983",
        "publication_date": "2025-07-30",
        "description": "<p>This study aimed to develop and optimize a bilayer tablet containing immediate-release amlodipine and sustained-release indapamide for the treatment of hypertension. Using BCPharSoft OPT software, individual layer formulations were optimized: 8.63% croscarmellose sodium for the amlodipine layer and 32.41% HPMC K15M with 4.51% PVP K30 for the indapamide layer. The final bilayer tablets exhibited hardness between 230 N and 260 N and a 3% weight gain after film coating, which had no significant effect on drug release. A validated HPLC\u2013DAD method, following ICH guidelines, confirmed the accurate quantification of both drugs across pH 1.2, 4.5, and 6.8. The method demonstrated high specificity, linearity, accuracy, precision, and robustness. Overall, the formulation achieved in-vitro dissolution equivalence to a reference commercial product.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Huynh, Duyen Thi My",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Duc Nguyen, Tuan",
            "affiliation": "University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam"
          },
          {
            "name": "Nguyen, Quyen Hoang",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Dao, Tai Nguyen Thanh",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Nguyen, An Doan Quynh",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Nguyen, Nguyen Ngoc Khoi",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Nguyen, Mai Thi Anh",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Huynh, Lan Kim",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Le, Minh-Ngoc Thi",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Nguyen, Tri Vinh",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Le, Phuoc Huu",
            "affiliation": "Ming Chi University of Technology, New Taipei City, Taiwan|Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          },
          {
            "name": "Khuu, Son Thanh",
            "affiliation": "Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam"
          }
        ],
        "keywords": [
          "amlodipine",
          "indapamide",
          "bilayer tablet",
          "HPLC\u2013DAD",
          "formulation optimization"
        ],
        "related_identifiers": [
          {
            "identifier": "10.3897/pharmacia.72.e155983.figure4",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e155983.figure2",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e155983.figure3",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e155983.figure1",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e155983.suppl1",
            "relation": "hasPart",
            "resource_type": "other",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.jddst.2020.102079",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.3109/03639049709150550",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.3329/dujps.v10i2.11785",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1161/HYPERTENSIONAHA.119.13437",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1161/HYPERTENSIONAHA.119.13437",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.mcna.2015.02.004",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.7324/JAPS.2013.3516",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.7324/JAPS.2023.114417",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.heliyon.2023.e16592",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1371/journal.pone.0092955",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.ejpb.2021.02.011",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1186/s12872-022-02514-y",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1177/009286159703100426",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1161/CIRCULATIONAHA.115.018912",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.7324/JAPS.2012.2819",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1186/s13065-022-00904-z",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.15406/mojbb.2015.01.00014",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1093/eurheartj/ehy339",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.bbamem.2015.04.016",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          }
        ],
        "references": [
          "Akhtar M, Jamshaid M, Zaman M, Zeeshan AZ (2020) Bilayer tablets: A developing novel drug delivery system. Journal of Drug Delivery Science and Technology 60: 102079. https://doi.org/10.1016/j.jddst.2020.102079",
          "Alam MT, Alam S, Karim F, Naveed S, Qamar F, Sarwer G (2017) Formulation and Evaluation of Amlodipine Besylate Tablet by Direct Compression Method. RADS Journal of Pharmacy and Pharmaceutical Sciences 5: 57\u201361.",
          "Begum AA, Islam M, Wahed TB, Anisuzzaman S, Kundu SK (2011) Formulation, Evaluation and Optimization of Sustained Release Tablets of Indapamide using Hydrophilic Matrix system. International Journal of PharmTech Research 3: 1831\u20131836.",
          "Becker D, Rigassi T, Bauer-brandl A (1997) Effectiveness of binders in wet granulation: a comparison using model formulations of different tabletability. Drug Development and Industrial Pharmacy 23: 791\u2013808. https://doi.org/10.3109/03639049709150550",
          "Das U, Halder S, Kabir AKL, Rashid H-O, Rouf ASS (2012) Development and in vitro Evaluation of Sustained Release Matrix Tablets of Indapamide from Methocel\u00ae K15 MCR and K100 LVCR. Dhaka University Journal of Pharmaceutical Sciences 10: 87\u201392. https://doi.org/10.3329/dujps.v10i2.11785",
          "Desai D, Wang J, Wen H, Li X, Timmins P (2013) Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharmaceutical Development and Technology 18: 1265\u20131276. https://doi.org/10.1161/HYPERTENSIONAHA.119.13437",
          "Dzau VJ, Balatbat CA (2019) Future of Hypertension - The Need for Transformation. Hypertension 74: 450. https://doi.org/10.1161/HYPERTENSIONAHA.119.13437",
          "EMA (2014) Guideline on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations, EMA: Singapore 44.",
          "Farooq U, Ray SG (2015) 2014 Guideline for the Management of High Blood Pressure (Eighth Joint National Committee): Take-Home Messages. The Medical Clinics of North America 99(4): 733\u2013738. https://doi.org/10.1016/j.mcna.2015.02.004",
          "FDA (2021) Development and Submission of Near Infrared Analytical Procedures Guidance for Industry, U.S. Department of Health and Human Services.",
          "Hossain A, Alam S, Paul P (2013) Development and Evaluation of Sustained Release Matrix Tablets of Indapamide using Methocel K15M CR. Journal of Applied Pharmaceutical Science 3: 85\u201390. https://doi.org/10.7324/JAPS.2013.3516",
          "Huynh DTM, Tran VH, Le M-NT, Huynh VH, Pham DT (2023) Floating tablets incorporating curcumin solid dispersion as a potential pharmaceutical dosage form for stomach cancer treatment. Journal of Applied Pharmaceutical Science 13: 240\u2013250. https://doi.org/10.7324/JAPS.2023.114417",
          "Huynh DTM, Hai HT, Hau NM, Lan HK, Vinh TP, Tran VD, Pham DT (2023) Preparations and characterizations of effervescent granules containing azithromycin solid dispersion for children and elder: Solubility enhancement, taste-masking, and digestive acidic protection. Heliyon 9: e16592. https://doi.org/10.1016/j.heliyon.2023.e16592",
          "ICH (1995) Topic Q2 (R1) Validation of Analytical Procedures: Text and Methodology - Step 5 Note for Guidance on Validation of Analytical Procedures: Text and Methodology (CPMP/ICH/381/95). European Medicines Agency 2: 1\u201315.",
          "Iqbal AM, Jamal SF (2023) Essential Hypertension. StatPearls Treasure Island (FL), 1\u201310. https://www.ncbi.nlm.nih.gov/books/NBK539859/",
          "Jadhav U, Hiremath J, Namjoshi DJ, Gujral VK, Tripathi KK (2014) Blood Pressure Control with a Single-Pill Combination of Indapamide Sustained-Release and Amlodipine in Patients with Hypertension: The EFFICIENT Study. PLOS ONE 9: e92955. https://doi.org/10.1371/journal.pone.0092955",
          "Khadka P, Sinha S, Tucker IG, Dummer J, Hill PC, Katare R, Das SC (2021) Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats. European Journal of Pharmaceutics and Biopharmaceutics 162: 1\u201311. https://doi.org/10.1016/j.ejpb.2021.02.011",
          "Kobalava ZD, Kolesnik EL, Shavarova EK, Goreva LA, Karapetyan LV (2022) Effectiveness of indapamide/amlodipine single\u2011pill combination in patients with isolated systolic hypertension: post\u2011hoc analysis of the ARBALET study. BMC Cardiovascular Disorders 22: 85. https://doi.org/10.1186/s12872-022-02514-y",
          "Liu J-P, Ma M-C, Chow S-C. (1997) Statistical evaluation of similarity factor f2 as a criterion for assessment of similarity between dissolution profiles. Drug Information Journal 31: 1255\u20131271. https://doi.org/10.1177/009286159703100426",
          "Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J (2016) Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-based Studies from 90 Countries. Circulation 134: 441\u2013450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912",
          "Narmada GY, Mohini K, Prakash RB, Gowrinath DXP, Kumar KS (2009) Formulation, Evaluation and Optimization of Fast Dissolving Tablets Containing Amlodipine Besylate by Sublimation Method. ARS Pharmaceutica 50: 129\u2013144.",
          "Raj BS, Punitha ISR, Dube S (2012) Formulation and Characterization of Fast Disintegrating tablets of Amlodipine using Super-disintegrants. Journal of Applied Pharmaceutical Science 02: 118\u2013123. https://doi.org/10.7324/JAPS.2012.2819",
          "Rahman MAA, Elghobashy MR, Zaazaa HE, Atty SA, El Mosallamy SS (2022) Validated HPLC\u2013PDA methodology utilized for simultaneous determination of Etoricoxib and Paracetamol in the presence of Paracetamol toxic impurities. BMC Chemistry 16: 108. https://doi.org/10.1186/s13065-022-00904-z",
          "Seitz JA, Flessland GM (1965) Evaluation of the Physical Properties of Compressed Tablets I Tablet Hardness and Friability. Journal of Pharmaceutical Sciences 54: 1353.",
          "Sheraz MA, Ahsan SF, Khan MF, Ahmed S, Ahmad I (2016) Formulations of Amlodipine: A Review. Journal of Pharmaceutics 2016: 8961621.",
          "Soni S, Verma A, Ram V (2015) Evaluation of chitosan\u2012hydroxy propyl methyl cellulose as a single unit hydrodynamically balanced sustained release matrices for stomach specific delivery of piroxicam. MOJ Bioequivalence & Bioavailability 1: 57\u201265. https://doi.org/10.15406/mojbb.2015.01.00014",
          "Srikar G, Gouthami KS, Manasa B, Sirisha AS (2013) Formulation optimization and characterization of amlodipine oral disintegrating tablets prepared by co-grinding technique. Der Pharmacia Lettre 5: 335\u2013343.",
          "United States Pharmacopoeial Convention (2019a) Amlodipine. in The United State Pharmacopeia 43/National Formulary-38.",
          "United States Pharmacopoeial Convention (2019b) Indapamide. in The United State Pharmacopeia 43/National Formulary-38.",
          "United States Pharmacopoeial Convention (2020) USP-NF The dissolution procedure: development and validation. The United State Pharmacopeia 43/National Formulary-38.",
          "Williams B, Mancia G, Spiering W, Rose EA, Azizi M, Burnier M (2018) 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. European Heart Journal 39(33): 3021\u20133104. https://doi.org/10.1093/eurheartj/ehy339",
          "Yousefpour A, Modarress H, Goharpey F, Amjad-iranagh S (2015) Interaction of PEGylated anti-hypertensive drugs, amlodipine, atenolol and lisinopril with lipid bilayer membrane: A molecular dynamics simulation study. Biochimica et Biophysica Acta 1848(8): 1687\u20131698. https://doi.org/10.1016/j.bbamem.2015.04.016"
        ],
        "resource_type": {
          "title": "Journal article",
          "type": "publication",
          "subtype": "article"
        },
        "journal": {
          "issue": "",
          "pages": "1-13",
          "title": "Pharmacia",
          "volume": "72"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16673809"
              }
            }
          ]
        }
      },
      "title": "Optimizing formulation and development of amlodipine-indapamide bilayer film-coated tablets with in vitro dissolution equivalence to a reference drug",
      "links": {
        "self": "https://zenodo.org/api/records/16673810",
        "self_html": "https://zenodo.org/records/16673810",
        "preview_html": "https://zenodo.org/records/16673810?preview=1",
        "doi": "https://doi.org/10.3897/pharmacia.72.e155983",
        "self_doi": "https://doi.org/10.3897/pharmacia.72.e155983",
        "self_doi_html": "https://zenodo.org/doi/10.3897/pharmacia.72.e155983",
        "reserve_doi": "https://zenodo.org/api/records/16673810/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16673809",
        "parent_html": "https://zenodo.org/records/16673809",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16673810/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16673810/sequence/default",
        "files": "https://zenodo.org/api/records/16673810/files",
        "media_files": "https://zenodo.org/api/records/16673810/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16673810:PHAR_article_155983.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16673810:PHAR_article_155983.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16673810:PHAR_article_155983.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16673810:PHAR_article_155983.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16673810:PHAR_article_155983.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16673810:PHAR_article_155983.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16673810/files-archive",
        "archive_media": "https://zenodo.org/api/records/16673810/media-files-archive",
        "latest": "https://zenodo.org/api/records/16673810/versions/latest",
        "latest_html": "https://zenodo.org/records/16673810/latest",
        "versions": "https://zenodo.org/api/records/16673810/versions",
        "draft": "https://zenodo.org/api/records/16673810/draft",
        "access_links": "https://zenodo.org/api/records/16673810/access/links",
        "access_grants": "https://zenodo.org/api/records/16673810/access/grants",
        "access_users": "https://zenodo.org/api/records/16673810/access/users",
        "access_request": "https://zenodo.org/api/records/16673810/access/request",
        "access": "https://zenodo.org/api/records/16673810/access",
        "communities": "https://zenodo.org/api/records/16673810/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16673810/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16673810/requests"
      },
      "updated": "2025-08-01T07:31:07.145029+00:00",
      "recid": "16673810",
      "revision": 4,
      "files": [
        {
          "id": "b20e2c3d-d070-41ac-944e-9a107cdd776a",
          "key": "PHAR_article_155983.xml",
          "size": 154489,
          "checksum": "md5:49d592ac146f09ea66d1126b68087916",
          "links": {
            "self": "https://zenodo.org/api/records/16673810/files/PHAR_article_155983.xml/content"
          }
        },
        {
          "id": "9eb933d3-309c-4094-bb46-1cde4e581b27",
          "key": "PHAR_article_155983.pdf",
          "size": 1804539,
          "checksum": "md5:e1887ead399bdbc3587b6dbff1ccbb6e",
          "links": {
            "self": "https://zenodo.org/api/records/16673810/files/PHAR_article_155983.pdf/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "22270"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 0,
        "unique_downloads": 0,
        "views": 0,
        "unique_views": 0,
        "version_downloads": 0,
        "version_unique_downloads": 0,
        "version_unique_views": 0,
        "version_views": 0
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-08-01T07:31:00.321433+00:00",
      "modified": "2025-08-01T07:31:00.758361+00:00",
      "id": 16673806,
      "conceptrecid": "16673805",
      "doi": "10.3897/pharmacia.72.e160997",
      "doi_url": "https://doi.org/10.3897/pharmacia.72.e160997",
      "metadata": {
        "title": "In situ development of an artificial intelligence (AI) model for early detection of adverse drug reactions (ADRs) to ensure drug safety",
        "doi": "10.3897/pharmacia.72.e160997",
        "publication_date": "2025-07-30",
        "description": "<p>Pharmacovigilance is a vital component of public health systems, aiming to ensure the safe use of medicinal products. In this study, an artificial intelligence (AI)-based model was developed using TensorFlow to predict the likelihood of adverse drug reactions (ADRs) based on molecular structure and predefined criteria. Data from DrugBank, MedDRA, and SIDER databases were extracted, integrated, and structured in a relational model. A feedforward neural network was trained using chemical and pharmacological descriptors such as SMILES and ATC codes. The model showed consistent performance in estimating ADR risk, highlighting the potential role of AI in supporting early safety assessments. This method may enhance post-marketing surveillance through more timely and data-driven risk identification. Despite certain limitations, AI-assisted modeling represents a valuable addition to pharmacovigilance and patient safety awareness strategies.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Ruseva, Veselina",
            "affiliation": "Medical University of Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Dobrev, Stanimir",
            "affiliation": "Medical University of Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Getova-Kolarova, Violeta",
            "affiliation": "Medical University of Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Peneva, Anna",
            "affiliation": "Medical University of Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Getov, Ilko",
            "affiliation": "Medical University of Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Dimitrova, Maria",
            "affiliation": "Medical University of Sofia, Sofia, Bulgaria"
          },
          {
            "name": "Petkova, Valentina",
            "affiliation": "Medical University of Sofia, Sofia, Bulgaria"
          }
        ],
        "keywords": [
          "pharmacovigilance",
          "artificial intelligence",
          "adverse drug reactions",
          "machine learning",
          "neural networks"
        ],
        "related_identifiers": [
          {
            "identifier": "10.3897/pharmacia.72.e160997.figure5",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e160997.figure3",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e160997.figure4",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e160997.figure1",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.3897/pharmacia.72.e160997.figure2",
            "relation": "hasPart",
            "resource_type": "image-figure",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.ejphar.2014.07.025",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1186/s12859-018-2544-0",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1111/bcp.13514",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1038/s41598-024-74505-2",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.2165/00002018-200629050-00003",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.3389/fphar.2024.1497397",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1001/jama.279.15.1200",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.3390/ijms25084516",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1142/S0219720020500468",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1002/pds.3309",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.3389/fddsv.2021.768792",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1136/bmj.329.7456.15",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1038/s41746-018-0029-1",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1016/j.glmedi.2024.100139",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.3233/JAD-220883",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1371/journal.pone.0041471",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          },
          {
            "identifier": "10.1038/s41467-024-49388-6",
            "relation": "cites",
            "resource_type": "publication",
            "scheme": "doi"
          }
        ],
        "references": [
          "Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action and side effects. European Journal of Pharmacology 740: 364\u2013378. https://doi.org/10.1016/j.ejphar.2014.07.025",
          "Dey S, Luo H, Fokoue A, Hu J, Zhang P (2018) Predicting adverse drug reactions through interpretable deep learning framework. BMC Bioinformatics 19: 476. https://doi.org/10.1186/s12859-018-2544-0",
          "EMA [European Medicines Agency] (2023) Reflection paper on the use of Artificial Intelligence (AI) in the lifecycle of medicines. EMA/226338/2023. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-lifecycle-medicines_en.pdf",
          "Falconer N, Barras M, Cottrell N (2018) Systematic review of predictive risk models for adverse drug events in hospitalized patients. British Journal of Clinical Pharmacology 84(5): 846\u2013864. https://doi.org/10.1111/bcp.13514",
          "Farnoush A, Sedighi-Maman Z, Rasoolian B, Heath JJ, Fallah B (2024) Prediction of adverse drug reactions using demographic and non-clinical drug characteristics in FAERS data. Scientific Reports 14: 23636. https://doi.org/10.1038/s41598-024-74505-2",
          "FDA [U.S. Food and Drug Administration] (2021) Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. https://www.fda.gov/media/145022/download",
          "Hazell L, Shakir SAW (2006) Under-reporting of adverse drug reactions. Drug Safety 29(5): 385\u2013396. https://doi.org/10.2165/00002018-200629050-00003",
          "Hu Q, Chen Y, Zou D, He Z, Xu T (2024) Predicting adverse drug event using machine learning based on electronic health records: a systematic review and meta- analysis. Frontiers in Pharmacology 15: 1497397. https://doi.org/10.3389/fphar.2024.1497397",
          "Kwak H, Lee M, Yoon S (2004) Drug\u2013disease graph: predicting adverse drug reaction signals via graph neural network with clinical data. arXiv: 00407.",
          "Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15): 1200\u20131205. https://doi.org/10.1001/jama.279.15.1200",
          "Lin Z, Gong Y, Bender A, Coley CW (2024) MoLFormer-XL: Large chemical language model for molecular property prediction. Journal of Chemical Information and Modeling 64(3): 782\u2013794.",
          "Lin J, He Y, Ru C, Long W, Li M, Wen Z (2024) Advancing adverse drug reaction prediction with deep chemical language model for drug safety evaluation. International Journal of Molecular Sciences 25(8): 4516. https://doi.org/10.3390/ijms25084516",
          "Liu M, Wei Y, Lv L, Yang J, Yan C, Hu X (2023) Integrated graph-based model for predicting adverse drug reactions using multiple heterogeneous data. BMC Medical Informatics and Decision Making 23(1): 14.",
          "Mantripragada AS, Teja SP, Katasani RR, Joshi P, Masilamani V, Ramesh R (2021) Prediction of adverse drug reactions using drug convolutional neural networks. Journal of Bioinformatics and Computational Biology 19(1): 2050046. https://doi.org/10.1142/S0219720020500468",
          "Miguel A, Azevedo LF, Ara\u00fajo M, Pereira AC (2012) Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety 21(11): 1139\u20131154. https://doi.org/10.1002/pds.3309",
          "Mohsen A, Tripathi LP, Mizuguchi K. Deep Learning Prediction of Adverse Drug Reactions in Drug Discovery Using Open TG\u2013GATEs and FAERS Databases. Frontiers in Drug Discovery 1: 768792. https://doi.org/10.3389/fddsv.2021.768792",
          "Montastruc JL, Lapeyre-Mestre M (2023) Artificial intelligence and pharmacovigilance: Synergy or substitution? Drug Safety 46(1): 3\u20136.",
          "Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456): 15\u201319. https://doi.org/10.1136/bmj.329.7456.15",
          "Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, Liu PJ, Liu X, Marcus J, Sun M, Sundberg P, Yee H, Zhang K, Zhang Y, Flores G, Duggan GE, Irvine J, Le Q Litsch K, Mossin A, Tansuwan J, De Wang Wexler J, Wilson J, Ludwig D, Volchenboum SL, Chou K, Pearson M, Madabushi S, Shah NH, Butte AJ, Howell MD, Cui C, Corrado GS, Dean J (2018) Scalable and accurate deep learning with electronic health records. npj Digital Medicine 1: 18. https://doi.org/10.1038/s41746-018-0029-1",
          "Shamim MA, Shamim MA, Arora P, Dwivedi P (2024) Artificial intelligence and big data for pharmacovigilance and patient safety.Journal of Medicine, Surgery, and Public Health 3: 100139. https://doi.org/10.1016/j.glmedi.2024.100139",
          "Sundararajan M, Taly A, Yan Q (2017) Axiomatic Attribution for Deep Networks. Proceedings of Machine Learning Research 70: 3319\u20133328.",
          "Verwaerde P, Estrella C, Burlet S, Barrier M, Marotte AA, Clincke G (2024) First-in-human safety, tolerability, and pharmacokinetics of single and multiple doses of AZP2006 (Ezeprogind) in healthy volunteers. Journal of Alzheimer's Disease 98(2): 715\u2013727. https://doi.org/10.3233/JAD-220883",
          "Vilar S, Harpaz R, Santana L, Uriarte E, Friedman C (2012) Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS One. 7(7): e41471. https://doi.org/10.1371/journal.pone.0041471",
          "Wang Y, Guo M, Zhang Y, Wang Y, Liu S, Pan Y (2024) Molecular graph representation learning with feature-wise attention for adverse drug reaction prediction. Scientific Reports 14: 2849.",
          "Wu JN, Wang T, Chen Y, Tang LJ, Wu HL, Yu RQ (2011) t-SMILES: a fragment-based molecular representation framework for de novo ligand design. Nature Communications 15(1): 4993. https://doi.org/10.1038/s41467-024-49388-6"
        ],
        "resource_type": {
          "title": "Journal article",
          "type": "publication",
          "subtype": "article"
        },
        "journal": {
          "issue": "",
          "pages": "1-8",
          "title": "Pharmacia",
          "volume": "72"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16673805"
              }
            }
          ]
        }
      },
      "title": "In situ development of an artificial intelligence (AI) model for early detection of adverse drug reactions (ADRs) to ensure drug safety",
      "links": {
        "self": "https://zenodo.org/api/records/16673806",
        "self_html": "https://zenodo.org/records/16673806",
        "preview_html": "https://zenodo.org/records/16673806?preview=1",
        "doi": "https://doi.org/10.3897/pharmacia.72.e160997",
        "self_doi": "https://doi.org/10.3897/pharmacia.72.e160997",
        "self_doi_html": "https://zenodo.org/doi/10.3897/pharmacia.72.e160997",
        "reserve_doi": "https://zenodo.org/api/records/16673806/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16673805",
        "parent_html": "https://zenodo.org/records/16673805",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16673806/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16673806/sequence/default",
        "files": "https://zenodo.org/api/records/16673806/files",
        "media_files": "https://zenodo.org/api/records/16673806/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16673806:PHAR_article_160997.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16673806:PHAR_article_160997.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16673806:PHAR_article_160997.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16673806:PHAR_article_160997.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16673806:PHAR_article_160997.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16673806:PHAR_article_160997.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16673806/files-archive",
        "archive_media": "https://zenodo.org/api/records/16673806/media-files-archive",
        "latest": "https://zenodo.org/api/records/16673806/versions/latest",
        "latest_html": "https://zenodo.org/records/16673806/latest",
        "versions": "https://zenodo.org/api/records/16673806/versions",
        "draft": "https://zenodo.org/api/records/16673806/draft",
        "access_links": "https://zenodo.org/api/records/16673806/access/links",
        "access_grants": "https://zenodo.org/api/records/16673806/access/grants",
        "access_users": "https://zenodo.org/api/records/16673806/access/users",
        "access_request": "https://zenodo.org/api/records/16673806/access/request",
        "access": "https://zenodo.org/api/records/16673806/access",
        "communities": "https://zenodo.org/api/records/16673806/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16673806/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16673806/requests"
      },
      "updated": "2025-08-01T07:31:00.758361+00:00",
      "recid": "16673806",
      "revision": 4,
      "files": [
        {
          "id": "18b1f44b-7cfc-43ad-9798-b23ce2eb74d0",
          "key": "PHAR_article_160997.pdf",
          "size": 878210,
          "checksum": "md5:85f50edf3135128e5f89c2c5bf1f2f6d",
          "links": {
            "self": "https://zenodo.org/api/records/16673806/files/PHAR_article_160997.pdf/content"
          }
        },
        {
          "id": "b88e8aa5-c7c4-456c-9443-19ae89223e67",
          "key": "PHAR_article_160997.xml",
          "size": 66791,
          "checksum": "md5:066b3863f84c6d45021b613e73cbf5a4",
          "links": {
            "self": "https://zenodo.org/api/records/16673806/files/PHAR_article_160997.xml/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "22270"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 0,
        "unique_downloads": 0,
        "views": 0,
        "unique_views": 0,
        "version_downloads": 0,
        "version_unique_downloads": 0,
        "version_unique_views": 0,
        "version_views": 0
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-07-30T17:42:35.975489+00:00",
      "modified": "2025-07-30T17:42:36.222516+00:00",
      "id": 16617882,
      "conceptrecid": "16617881",
      "doi": "10.5281/zenodo.16617882",
      "conceptdoi": "10.5281/zenodo.16617881",
      "doi_url": "https://doi.org/10.5281/zenodo.16617882",
      "metadata": {
        "title": "PREECLAMPSIA MANEJO EN BASE A FACTORES ANGIOGENICOS",
        "doi": "10.5281/zenodo.16617882",
        "publication_date": "2025-07-30",
        "description": "<p>La ponencia abord&oacute; el manejo de la preeclampsia basado en factores angiog&eacute;nicos, destacando su impacto como segunda causa de mortalidad materna en Ecuador (25-38% de casos entre 2021-2025). Se presentaron datos epidemiol&oacute;gicos nacionales que muestran una reducci&oacute;n progresiva en muertes maternas (180 en 2020 vs. 86 en 2024), aunque persisten desaf&iacute;os en provincias como Guayas y Pichincha. Fundamentado en evidencia de ensayos cl&iacute;nicos (<em>HYPITAT</em>,&nbsp;<em>PHOENIX</em>) y metaan&aacute;lisis, se analiz&oacute; el&nbsp;balance entre parto inmediato y manejo expectante: para preeclampsia leve &gt;37 semanas, el parto planificado reduce complicaciones maternas (RR 0.86; IC 0.79-0.94), pero entre 34-36.6 semanas aumenta riesgos neonatales (admisi&oacute;n a UCI neonatal: RR 2.0). Como eje innovador, se enfatiz&oacute; el rol de los&nbsp;biomarcadores angiog&eacute;nicos&nbsp;(ratio&nbsp;*sFlt-1/PlGF*):</p>\n<ul>\n<li>\n<p>Ratio &lt;38: Descarta preeclampsia en 1 semana (VPN 99.3%).</p>\n</li>\n<li>\n<p>Ratio 38-85: Requiere monitoreo estrecho cada 1-2 semanas.</p>\n</li>\n<li>\n<p>Ratio &gt;85 (antes de 34 semanas) o &gt;110 (despu&eacute;s de 34 semanas): Predice progresi&oacute;n a preeclampsia grave, indicando hospitalizaci&oacute;n, maduraci&oacute;n pulmonar fetal y posible interrupci&oacute;n en 48 horas.</p>\n</li>\n</ul>\n<p>&nbsp;</p>\n<p>Se presentaron algoritmos cl&iacute;nicos (aprobados por la FDA en 2023) que integran estos biomarcadores para decisiones de manejo ambulatorio/hospitalario, junto con estrategias de prevenci&oacute;n (AAS antes de semana 16 en alto riesgo). Las conclusiones subrayaron: 1) Finalizaci&oacute;n obligatoria a las 37 semanas, 2) Decisi&oacute;n individualizada entre 34-36.6 semanas con consentimiento informado, y 3) Clasificaci&oacute;n de preeclampsia en Tipo I (placentaria, temprana) y Tipo II (materna, tard&iacute;a) para abordaje personalizado.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Cartuche Macas, Angel Patricio",
            "affiliation": "Hospital Gineco Obst\u00e9trico Isidro Ayora"
          }
        ],
        "contributors": [
          {
            "name": "Central University of Ecuador",
            "affiliation": null,
            "type": "HostingInstitution"
          },
          {
            "name": "Hospital Gineco Obst\u00e9trico Isidro Ayora",
            "affiliation": null,
            "type": "HostingInstitution"
          }
        ],
        "keywords": [
          "Factores angiog\u00e9nicos",
          "preeclampsia",
          "Mortalidad materna"
        ],
        "dates": [
          {
            "type": "accepted"
          }
        ],
        "version": "1",
        "references": [
          "Mateus, J. (2014). Significancia del desbalance de los factores angiog\u00e9nicos en preeclampsia. Revista Peruana de Ginecolog\u00eda y Obstetricia, 60(4), 333-344.",
          "Reyna-Villasmil, E. (2018). Factores anti-angiog\u00e9nicos y preeclampsia. Avances en Biomedicina, 7(1), 23-34.",
          "Carbajal, L. M. G. (2014). Actualizaci\u00f3n en la fisiopatolo g\u00eda de la preeclampsia. Revista peruana de ginecolog\u00eda y obstetricia, 60(4), 321-331."
        ],
        "resource_type": {
          "title": "Presentation",
          "type": "presentation"
        },
        "meeting": {
          "title": "Ponencia Internacional",
          "place": "Hospital Gineco Obst\u00e9trico Isidro Ayora",
          "url": "https://hgoia.gob.ec/index.php/component/users/?view=remind",
          "session": "2"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "communities": [
          {
            "id": "iisimposioobstetriconeonatal"
          }
        ],
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16617881"
              }
            }
          ]
        }
      },
      "title": "PREECLAMPSIA MANEJO EN BASE A FACTORES ANGIOGENICOS",
      "links": {
        "self": "https://zenodo.org/api/records/16617882",
        "self_html": "https://zenodo.org/records/16617882",
        "preview_html": "https://zenodo.org/records/16617882?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.16617882",
        "self_doi": "https://doi.org/10.5281/zenodo.16617882",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16617882",
        "reserve_doi": "https://zenodo.org/api/records/16617882/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16617881",
        "parent_html": "https://zenodo.org/records/16617881",
        "parent_doi": "https://doi.org/10.5281/zenodo.16617881",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16617881",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16617882/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16617882/sequence/default",
        "files": "https://zenodo.org/api/records/16617882/files",
        "media_files": "https://zenodo.org/api/records/16617882/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16617882:10.%20Patricio%20Cartuche%20VF.pptx.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16617882:10.%20Patricio%20Cartuche%20VF.pptx.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16617882:10.%20Patricio%20Cartuche%20VF.pptx.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16617882:10.%20Patricio%20Cartuche%20VF.pptx.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16617882:10.%20Patricio%20Cartuche%20VF.pptx.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16617882:10.%20Patricio%20Cartuche%20VF.pptx.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16617882/files-archive",
        "archive_media": "https://zenodo.org/api/records/16617882/media-files-archive",
        "latest": "https://zenodo.org/api/records/16617882/versions/latest",
        "latest_html": "https://zenodo.org/records/16617882/latest",
        "versions": "https://zenodo.org/api/records/16617882/versions",
        "draft": "https://zenodo.org/api/records/16617882/draft",
        "access_links": "https://zenodo.org/api/records/16617882/access/links",
        "access_grants": "https://zenodo.org/api/records/16617882/access/grants",
        "access_users": "https://zenodo.org/api/records/16617882/access/users",
        "access_request": "https://zenodo.org/api/records/16617882/access/request",
        "access": "https://zenodo.org/api/records/16617882/access",
        "communities": "https://zenodo.org/api/records/16617882/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16617882/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16617882/requests"
      },
      "updated": "2025-07-30T17:42:36.222516+00:00",
      "recid": "16617882",
      "revision": 4,
      "files": [
        {
          "id": "afc727f0-adf2-416d-9618-eb38175a7c73",
          "key": "10. Patricio Cartuche VF.pptx.pdf",
          "size": 7822827,
          "checksum": "md5:e27555f447e482a2c453dc4fbe349381",
          "links": {
            "self": "https://zenodo.org/api/records/16617882/files/10. Patricio Cartuche VF.pptx.pdf/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "1120032"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 15,
        "unique_downloads": 10,
        "views": 31,
        "unique_views": 31,
        "version_downloads": 15,
        "version_unique_downloads": 10,
        "version_unique_views": 31,
        "version_views": 31
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-07-30T13:58:59.287086+00:00",
      "modified": "2025-07-30T13:58:59.598357+00:00",
      "id": 16612913,
      "conceptrecid": "16612912",
      "doi": "10.5281/zenodo.16612913",
      "conceptdoi": "10.5281/zenodo.16612912",
      "doi_url": "https://doi.org/10.5281/zenodo.16612913",
      "metadata": {
        "title": "30th Argos Community Call",
        "doi": "10.5281/zenodo.16612913",
        "publication_date": "2025-07-30",
        "description": "<p><strong>30th Argos Community Call, 30 July 2025</strong></p>\n<p><span dir=\"auto\"><strong>Main topic:</strong></span></p>\n<p>During this month's call Pedro Pr&iacute;ncipe, from University of Minho, presented the collective work in Portugal to bring DMPs closer to the research practice through the <a href=\"https://opendmp.portaberta.pt\" target=\"_blank\" rel=\"noopener\">PortAberta</a> tool which is based on ARGOS/OpenCDMP software.</p>\n<p><span dir=\"auto\">Argos:&nbsp;</span><span dir=\"auto\"><a href=\"https://argos.openaire.eu/\" target=\"_blank\" rel=\"noopener\">https://argos.openaire.eu</a></span>&nbsp;</p>\n<p>Recording: <a href=\"https://youtu.be/BcjMD6Fixy0\" target=\"_blank\" rel=\"noopener\">https://youtu.be/BcjMD6Fixy0</a></p>\n<p>Argos Community Calls: <a href=\"https://www.openaire.eu/argos-community-calls\" target=\"_blank\" rel=\"noopener\">https://www.openaire.eu/argos-community-calls</a></p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Pr\u00edncipe, Pedro",
            "affiliation": "University of Minho",
            "orcid": "0000-0002-8588-4196"
          }
        ],
        "keywords": [
          "OpenAIRE",
          "Argos",
          "DMP",
          "PortAberta",
          "tool",
          "OpenCDMP"
        ],
        "resource_type": {
          "title": "Presentation",
          "type": "presentation"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "communities": [
          {
            "id": "openaire"
          }
        ],
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16612912"
              }
            }
          ]
        }
      },
      "title": "30th Argos Community Call",
      "links": {
        "self": "https://zenodo.org/api/records/16612913",
        "self_html": "https://zenodo.org/records/16612913",
        "preview_html": "https://zenodo.org/records/16612913?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.16612913",
        "self_doi": "https://doi.org/10.5281/zenodo.16612913",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16612913",
        "reserve_doi": "https://zenodo.org/api/records/16612913/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16612912",
        "parent_html": "https://zenodo.org/records/16612912",
        "parent_doi": "https://doi.org/10.5281/zenodo.16612912",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16612912",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16612913/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16612913/sequence/default",
        "files": "https://zenodo.org/api/records/16612913/files",
        "media_files": "https://zenodo.org/api/records/16612913/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16612913:Argos_CommunityCall_PortAberta_PedroPrincipe_20250730.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16612913:Argos_CommunityCall_PortAberta_PedroPrincipe_20250730.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16612913:Argos_CommunityCall_PortAberta_PedroPrincipe_20250730.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16612913:Argos_CommunityCall_PortAberta_PedroPrincipe_20250730.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16612913:Argos_CommunityCall_PortAberta_PedroPrincipe_20250730.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16612913:Argos_CommunityCall_PortAberta_PedroPrincipe_20250730.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16612913/files-archive",
        "archive_media": "https://zenodo.org/api/records/16612913/media-files-archive",
        "latest": "https://zenodo.org/api/records/16612913/versions/latest",
        "latest_html": "https://zenodo.org/records/16612913/latest",
        "versions": "https://zenodo.org/api/records/16612913/versions",
        "draft": "https://zenodo.org/api/records/16612913/draft",
        "access_links": "https://zenodo.org/api/records/16612913/access/links",
        "access_grants": "https://zenodo.org/api/records/16612913/access/grants",
        "access_users": "https://zenodo.org/api/records/16612913/access/users",
        "access_request": "https://zenodo.org/api/records/16612913/access/request",
        "access": "https://zenodo.org/api/records/16612913/access",
        "communities": "https://zenodo.org/api/records/16612913/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16612913/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16612913/requests"
      },
      "updated": "2025-07-30T13:58:59.598357+00:00",
      "recid": "16612913",
      "revision": 4,
      "files": [
        {
          "id": "6f92c23f-c626-4edb-9f22-56aee85c0977",
          "key": "Argos_CommunityCall_PortAberta_PedroPrincipe_20250730.pdf",
          "size": 3759716,
          "checksum": "md5:91bee80d4d7c9275424c58a1a4f1941f",
          "links": {
            "self": "https://zenodo.org/api/records/16612913/files/Argos_CommunityCall_PortAberta_PedroPrincipe_20250730.pdf/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "80373"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 30,
        "unique_downloads": 15,
        "views": 33,
        "unique_views": 30,
        "version_downloads": 30,
        "version_unique_downloads": 15,
        "version_unique_views": 30,
        "version_views": 33
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-07-30T12:17:43.102081+00:00",
      "modified": "2025-07-30T12:17:43.544383+00:00",
      "id": 16608582,
      "conceptrecid": "16608581",
      "doi": "10.5281/zenodo.16608582",
      "conceptdoi": "10.5281/zenodo.16608581",
      "doi_url": "https://doi.org/10.5281/zenodo.16608582",
      "metadata": {
        "title": "Lecanemab: A Breakthrough in Alzheimer's Treatment and Therapeutics",
        "doi": "10.5281/zenodo.16608582",
        "publication_date": "2025-07-30",
        "description": "<p>A progressive neurodegenerative disorder Alzheimer&rsquo;s disease is characterised by memory loss and cognitive decline which primarily affect the elderly person. There have been few disease-modifying effects from traditional treatment options, which have mostly been symptomatic. By delaying the pathological progression of early Alzheimer's disease, lecanemab, a monoclonal antibody that targets soluble amyloid-beta protofibrils, has brought about a novel therapeutic approach. The development, mechanism of action, adverse effects, synthesis, clinical trial data, and marketing insights of lecanemab are all examined in this article. Early-stage patients' cognitive slowing has shown statistically significant results in the pivotal CLARITY-AD trial. However, there are also significant side effects linked to lecanemab use, including neuropsychiatric symptoms, infusion-related reactions, and amyloid-related imaging abnormalities (ARIA). Careful patient monitoring is required because post-marketing data, such as pharmacovigilance analysis from the FDA Adverse Event Reporting System (FAERS), highlights uncommon but serious events, including deaths. The article also covers future directions in Alzheimer's therapy, regulatory milestones, and formulation strategies. Lecanemab, a first-generation disease-modifying drug in this class, exemplifies both the advancement of science and the difficulty of converting laboratory results into clinical use.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Arpita Lad*, Ishi Kumari, Harsha Jagtap, Mansi Matkar",
            "affiliation": null
          }
        ],
        "keywords": [
          "Alzheimer's disease, Lecanemab, Amyloid-beta protofibrils, CLARITY-AD trial, Disease-modifying therapy"
        ],
        "resource_type": {
          "title": "Journal article",
          "type": "publication",
          "subtype": "article"
        },
        "journal": {
          "issue": "7",
          "pages": "4076-4091",
          "title": "International Journal of Pharmaceutical Sciences",
          "volume": "3"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "communities": [
          {
            "id": "ijpsjournal"
          }
        ],
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16608581"
              }
            }
          ]
        }
      },
      "title": "Lecanemab: A Breakthrough in Alzheimer's Treatment and Therapeutics",
      "links": {
        "self": "https://zenodo.org/api/records/16608582",
        "self_html": "https://zenodo.org/records/16608582",
        "preview_html": "https://zenodo.org/records/16608582?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.16608582",
        "self_doi": "https://doi.org/10.5281/zenodo.16608582",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16608582",
        "reserve_doi": "https://zenodo.org/api/records/16608582/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16608581",
        "parent_html": "https://zenodo.org/records/16608581",
        "parent_doi": "https://doi.org/10.5281/zenodo.16608581",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16608581",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16608582/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16608582/sequence/default",
        "files": "https://zenodo.org/api/records/16608582/files",
        "media_files": "https://zenodo.org/api/records/16608582/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16608582:184-Review%20paper-Arpita%20Lad.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16608582:184-Review%20paper-Arpita%20Lad.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16608582:184-Review%20paper-Arpita%20Lad.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16608582:184-Review%20paper-Arpita%20Lad.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16608582:184-Review%20paper-Arpita%20Lad.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16608582:184-Review%20paper-Arpita%20Lad.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16608582/files-archive",
        "archive_media": "https://zenodo.org/api/records/16608582/media-files-archive",
        "latest": "https://zenodo.org/api/records/16608582/versions/latest",
        "latest_html": "https://zenodo.org/records/16608582/latest",
        "versions": "https://zenodo.org/api/records/16608582/versions",
        "draft": "https://zenodo.org/api/records/16608582/draft",
        "access_links": "https://zenodo.org/api/records/16608582/access/links",
        "access_grants": "https://zenodo.org/api/records/16608582/access/grants",
        "access_users": "https://zenodo.org/api/records/16608582/access/users",
        "access_request": "https://zenodo.org/api/records/16608582/access/request",
        "access": "https://zenodo.org/api/records/16608582/access",
        "communities": "https://zenodo.org/api/records/16608582/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16608582/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16608582/requests"
      },
      "updated": "2025-07-30T12:17:43.544383+00:00",
      "recid": "16608582",
      "revision": 4,
      "files": [
        {
          "id": "ad9a5189-c79d-4bd3-aa8f-16b0162c456c",
          "key": "184-Review paper-Arpita Lad.pdf",
          "size": 4327280,
          "checksum": "md5:f8fd80dde06038f33d45cb14596f11ac",
          "links": {
            "self": "https://zenodo.org/api/records/16608582/files/184-Review paper-Arpita Lad.pdf/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "252396"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 4,
        "unique_downloads": 2,
        "views": 2,
        "unique_views": 2,
        "version_downloads": 4,
        "version_unique_downloads": 2,
        "version_unique_views": 2,
        "version_views": 2
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-07-29T15:55:30.143353+00:00",
      "modified": "2025-07-29T15:55:30.463880+00:00",
      "id": 16575676,
      "conceptrecid": "16575675",
      "doi": "10.5281/zenodo.16575676",
      "conceptdoi": "10.5281/zenodo.16575675",
      "doi_url": "https://doi.org/10.5281/zenodo.16575676",
      "metadata": {
        "title": "Perspectives and Insights on Antineoplastic Agents with Diverse Mechanisms of Action (L01XX): From Development to New Drug Application (NDA) Submission for FDA",
        "doi": "10.5281/zenodo.16575676",
        "publication_date": "2025-07-29",
        "description": "<p><span lang=\"EN-US\">Combinations of antineoplastic agents (ATC code L01XY) are critical in modern oncology, leveraging synergistic mechanisms to enhance efficacy against hematologic and solid tumors. These therapies combine cytotoxic, targeted, and immunotherapeutic agents to overcome resistance and improve patient outcomes, addressing the global cancer burden projected to reach 28.4 million cases by 2040. This article reviews the L01XY class&rsquo;s pharmacology, chemical properties, container closure systems, safety profiles, and emerging technologies, such as nanoparticle delivery and biomarker-driven regimens. It also outlines the regulatory pathway for submitting a New Drug Submission (NDS) to Health Canada, aligning with the Food and Drugs Act, Health Canada regulations, and ICH guidelines. Recommendations emphasize early regulatory engagement, robust pharmacovigilance, and innovative delivery systems to ensure safe, effective, and accessible therapie.</span></p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Patel, Ishaben",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Chauhan, Ishaben",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Pirouzi, Peivand",
            "affiliation": "Crown College of Canada"
          }
        ],
        "resource_type": {
          "title": "Publication",
          "type": "publication"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16575675"
              }
            }
          ]
        }
      },
      "title": "Perspectives and Insights on Antineoplastic Agents with Diverse Mechanisms of Action (L01XX): From Development to New Drug Application (NDA) Submission for FDA",
      "links": {
        "self": "https://zenodo.org/api/records/16575676",
        "self_html": "https://zenodo.org/records/16575676",
        "preview_html": "https://zenodo.org/records/16575676?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.16575676",
        "self_doi": "https://doi.org/10.5281/zenodo.16575676",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16575676",
        "reserve_doi": "https://zenodo.org/api/records/16575676/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16575675",
        "parent_html": "https://zenodo.org/records/16575675",
        "parent_doi": "https://doi.org/10.5281/zenodo.16575675",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16575675",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16575676/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16575676/sequence/default",
        "files": "https://zenodo.org/api/records/16575676/files",
        "media_files": "https://zenodo.org/api/records/16575676/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16575676:Antineoplastic%20Agents%20L01XY%20-%20Crown%20College%20of%20Canada.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16575676:Antineoplastic%20Agents%20L01XY%20-%20Crown%20College%20of%20Canada.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16575676:Antineoplastic%20Agents%20L01XY%20-%20Crown%20College%20of%20Canada.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16575676:Antineoplastic%20Agents%20L01XY%20-%20Crown%20College%20of%20Canada.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16575676:Antineoplastic%20Agents%20L01XY%20-%20Crown%20College%20of%20Canada.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16575676:Antineoplastic%20Agents%20L01XY%20-%20Crown%20College%20of%20Canada.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16575676/files-archive",
        "archive_media": "https://zenodo.org/api/records/16575676/media-files-archive",
        "latest": "https://zenodo.org/api/records/16575676/versions/latest",
        "latest_html": "https://zenodo.org/records/16575676/latest",
        "versions": "https://zenodo.org/api/records/16575676/versions",
        "draft": "https://zenodo.org/api/records/16575676/draft",
        "access_links": "https://zenodo.org/api/records/16575676/access/links",
        "access_grants": "https://zenodo.org/api/records/16575676/access/grants",
        "access_users": "https://zenodo.org/api/records/16575676/access/users",
        "access_request": "https://zenodo.org/api/records/16575676/access/request",
        "access": "https://zenodo.org/api/records/16575676/access",
        "communities": "https://zenodo.org/api/records/16575676/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16575676/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16575676/requests"
      },
      "updated": "2025-07-29T15:55:30.463880+00:00",
      "recid": "16575676",
      "revision": 4,
      "files": [
        {
          "id": "b402941a-c003-442b-afc5-aef3ea067085",
          "key": "Antineoplastic Agents L01XY - Crown College of Canada.pdf",
          "size": 465253,
          "checksum": "md5:f6159a12f585aafe1d8351a31a2c670e",
          "links": {
            "self": "https://zenodo.org/api/records/16575676/files/Antineoplastic Agents L01XY - Crown College of Canada.pdf/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "1228454"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 4,
        "unique_downloads": 3,
        "views": 3,
        "unique_views": 3,
        "version_downloads": 4,
        "version_unique_downloads": 3,
        "version_unique_views": 3,
        "version_views": 3
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-07-29T15:51:21.691300+00:00",
      "modified": "2025-07-29T15:51:22.339552+00:00",
      "id": 16575565,
      "conceptrecid": "16575564",
      "doi": "10.5281/zenodo.16575565",
      "conceptdoi": "10.5281/zenodo.16575564",
      "doi_url": "https://doi.org/10.5281/zenodo.16575565",
      "metadata": {
        "title": "Perspectives and Insights on Antineoplastic Agents with Diverse Mechanisms of Action (L01XX): From Development to New Drug Application (NDA) Submission for FDA",
        "doi": "10.5281/zenodo.16575565",
        "publication_date": "2025-07-29",
        "description": "<p>Diverse Antineoplastic agents ATC category known as &ldquo;Other antineoplastic agents&rdquo; (L01XX) encompass a diverse group of drugs targeting novel molecular pathways to treat hematologic malignancies and solid tumors, addressing unmet needs in conditions like myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and other resistant cancers. These agents, including topoisomerase inhibitors, enzyme therapies, metal-based compounds, immunotoxins, COX-2 inhibitors, and platelet-reducing agents, offer unique mechanisms to improve patient outcomes. This article reviews the L01XX class&rsquo;s pharmacology, chemical properties, container closure systems, safety profiles, and emerging technologies, such as nanoparticle delivery and precision oncology. It also outlines the regulatory pathway for submitting a New Drug Application (NDA) to the FDA, aligning with the Federal Food, Drug, and Cosmetic Act, FDA regulations, and ICH guidelines. Recommendations emphasize early regulatory engagement, robust pharmacovigilance, and innovative delivery systems to ensure safe, effective, and accessible therapies.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Panchal, Suhasi",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Kumari, Priyanka",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Pirouzi, Peivand",
            "affiliation": "Crown College of Canada"
          }
        ],
        "resource_type": {
          "title": "Publication",
          "type": "publication"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16575564"
              }
            }
          ]
        }
      },
      "title": "Perspectives and Insights on Antineoplastic Agents with Diverse Mechanisms of Action (L01XX): From Development to New Drug Application (NDA) Submission for FDA",
      "links": {
        "self": "https://zenodo.org/api/records/16575565",
        "self_html": "https://zenodo.org/records/16575565",
        "preview_html": "https://zenodo.org/records/16575565?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.16575565",
        "self_doi": "https://doi.org/10.5281/zenodo.16575565",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16575565",
        "reserve_doi": "https://zenodo.org/api/records/16575565/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16575564",
        "parent_html": "https://zenodo.org/records/16575564",
        "parent_doi": "https://doi.org/10.5281/zenodo.16575564",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16575564",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16575565/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16575565/sequence/default",
        "files": "https://zenodo.org/api/records/16575565/files",
        "media_files": "https://zenodo.org/api/records/16575565/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16575565:Antineoplastic%20Agents%20L01XX%20-%20Crown%20College%20of%20Canada.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16575565:Antineoplastic%20Agents%20L01XX%20-%20Crown%20College%20of%20Canada.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16575565:Antineoplastic%20Agents%20L01XX%20-%20Crown%20College%20of%20Canada.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16575565:Antineoplastic%20Agents%20L01XX%20-%20Crown%20College%20of%20Canada.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16575565:Antineoplastic%20Agents%20L01XX%20-%20Crown%20College%20of%20Canada.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16575565:Antineoplastic%20Agents%20L01XX%20-%20Crown%20College%20of%20Canada.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16575565/files-archive",
        "archive_media": "https://zenodo.org/api/records/16575565/media-files-archive",
        "latest": "https://zenodo.org/api/records/16575565/versions/latest",
        "latest_html": "https://zenodo.org/records/16575565/latest",
        "versions": "https://zenodo.org/api/records/16575565/versions",
        "draft": "https://zenodo.org/api/records/16575565/draft",
        "access_links": "https://zenodo.org/api/records/16575565/access/links",
        "access_grants": "https://zenodo.org/api/records/16575565/access/grants",
        "access_users": "https://zenodo.org/api/records/16575565/access/users",
        "access_request": "https://zenodo.org/api/records/16575565/access/request",
        "access": "https://zenodo.org/api/records/16575565/access",
        "communities": "https://zenodo.org/api/records/16575565/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16575565/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16575565/requests"
      },
      "updated": "2025-07-29T15:51:22.339552+00:00",
      "recid": "16575565",
      "revision": 4,
      "files": [
        {
          "id": "dfffec69-d9f2-4371-b6f2-1b44ff70c8e8",
          "key": "Antineoplastic Agents L01XX - Crown College of Canada.pdf",
          "size": 464120,
          "checksum": "md5:d8292833b4aaf406af066c80a5cab65c",
          "links": {
            "self": "https://zenodo.org/api/records/16575565/files/Antineoplastic Agents L01XX - Crown College of Canada.pdf/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "1228454"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 6,
        "unique_downloads": 4,
        "views": 8,
        "unique_views": 7,
        "version_downloads": 6,
        "version_unique_downloads": 4,
        "version_unique_views": 7,
        "version_views": 8
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-07-29T15:46:32.799293+00:00",
      "modified": "2025-07-29T15:46:33.529059+00:00",
      "id": 16575400,
      "conceptrecid": "16575399",
      "doi": "10.5281/zenodo.16575400",
      "conceptdoi": "10.5281/zenodo.16575399",
      "doi_url": "https://doi.org/10.5281/zenodo.16575400",
      "metadata": {
        "title": "Perspectives and Insights on Antineoplastic Agents - Monoclonal Antibodies (L01XC): From Development to New Drug Application Submission for FDA",
        "doi": "10.5281/zenodo.16575400",
        "publication_date": "2025-07-29",
        "description": "<p>Monoclonal antibodies (mAbs), classified under ATC code L01XC, are a transformative class of antineoplastic agents that target tumor-specific antigens to treat cancers like lymphoma, breast cancer, and colorectal cancer. By binding to surface receptors or ligands, mAbs modulate oncogenic pathways or engage immune effector cells, offering precision over traditional chemotherapies. This article reviews the L01XC class&rsquo;s pharmacology, chemical properties, container closure systems, safety profiles, and emerging technologies, such as bispecific antibodies and immune checkpoint inhibitors. It also outlines the regulatory pathway for submitting a New Drug Application (NDA) to the FDA, aligning with the Federal Food, Drug, and Cosmetic Act, FDA regulations, and ICH guidelines. Recommendations emphasize early regulatory engagement, robust pharmacovigilance, and innovative delivery systems to ensure safe, effective, and accessible therapies.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Kumari, Priyanka",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Rajpurohit, Rekha",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Rathod, Riya",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Patel, Nilkumar",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Dhavala, Sunanda",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Doddipatla, Siri",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Pirouzi, Peivand",
            "affiliation": "Crown College of Canada"
          }
        ],
        "resource_type": {
          "title": "Publication",
          "type": "publication"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16575399"
              }
            }
          ]
        }
      },
      "title": "Perspectives and Insights on Antineoplastic Agents - Monoclonal Antibodies (L01XC): From Development to New Drug Application Submission for FDA",
      "links": {
        "self": "https://zenodo.org/api/records/16575400",
        "self_html": "https://zenodo.org/records/16575400",
        "preview_html": "https://zenodo.org/records/16575400?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.16575400",
        "self_doi": "https://doi.org/10.5281/zenodo.16575400",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16575400",
        "reserve_doi": "https://zenodo.org/api/records/16575400/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16575399",
        "parent_html": "https://zenodo.org/records/16575399",
        "parent_doi": "https://doi.org/10.5281/zenodo.16575399",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16575399",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16575400/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16575400/sequence/default",
        "files": "https://zenodo.org/api/records/16575400/files",
        "media_files": "https://zenodo.org/api/records/16575400/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16575400:Antineoplastic%20Agents%20L01XC%20-%20Crown%20College%20of%20Canada.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16575400:Antineoplastic%20Agents%20L01XC%20-%20Crown%20College%20of%20Canada.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16575400:Antineoplastic%20Agents%20L01XC%20-%20Crown%20College%20of%20Canada.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16575400:Antineoplastic%20Agents%20L01XC%20-%20Crown%20College%20of%20Canada.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16575400:Antineoplastic%20Agents%20L01XC%20-%20Crown%20College%20of%20Canada.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16575400:Antineoplastic%20Agents%20L01XC%20-%20Crown%20College%20of%20Canada.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16575400/files-archive",
        "archive_media": "https://zenodo.org/api/records/16575400/media-files-archive",
        "latest": "https://zenodo.org/api/records/16575400/versions/latest",
        "latest_html": "https://zenodo.org/records/16575400/latest",
        "versions": "https://zenodo.org/api/records/16575400/versions",
        "draft": "https://zenodo.org/api/records/16575400/draft",
        "access_links": "https://zenodo.org/api/records/16575400/access/links",
        "access_grants": "https://zenodo.org/api/records/16575400/access/grants",
        "access_users": "https://zenodo.org/api/records/16575400/access/users",
        "access_request": "https://zenodo.org/api/records/16575400/access/request",
        "access": "https://zenodo.org/api/records/16575400/access",
        "communities": "https://zenodo.org/api/records/16575400/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16575400/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16575400/requests"
      },
      "updated": "2025-07-29T15:46:33.529059+00:00",
      "recid": "16575400",
      "revision": 4,
      "files": [
        {
          "id": "0f06b60a-fa9d-49ee-85d2-7dcfda8cab9b",
          "key": "Antineoplastic Agents L01XC - Crown College of Canada.pdf",
          "size": 467427,
          "checksum": "md5:2cb7e30e23b3355f61920e16751c63bf",
          "links": {
            "self": "https://zenodo.org/api/records/16575400/files/Antineoplastic Agents L01XC - Crown College of Canada.pdf/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "1228454"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 13,
        "unique_downloads": 7,
        "views": 12,
        "unique_views": 6,
        "version_downloads": 13,
        "version_unique_downloads": 7,
        "version_unique_views": 6,
        "version_views": 12
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-07-29T15:03:51.378323+00:00",
      "modified": "2025-07-29T15:18:01.892872+00:00",
      "id": 16574281,
      "conceptrecid": "16574280",
      "doi": "10.5281/zenodo.16574281",
      "conceptdoi": "10.5281/zenodo.16574280",
      "doi_url": "https://doi.org/10.5281/zenodo.16574281",
      "metadata": {
        "title": "Perspectives and Insights on Anti-Dementia Drugs (N06): From Development to New Drug Application (NDA) development for FDA",
        "doi": "10.5281/zenodo.16574281",
        "publication_date": "2025-07-29",
        "description": "<p>Alzheimer&rsquo;s disease (AD), a progressive neurodegenerative disorder, imposes a significant burden on patients and healthcare systems due to amyloid-beta (A&beta;) plaque accumulation. Amyloid-targeting therapies, primarily monoclonal antibodies within the N06 therapeutic class, offer a disease-modifying approach by clearing amyloid plaques to slow cognitive decline in early-stage AD. These biologics, administered intravenously, require advanced diagnostics and carry risks like amyloid-related imaging abnormalities (ARIA). Despite modest efficacy and high costs, accelerated FDA approvals address unmet needs. This article explores the N06 class&rsquo;s pharmacology, formulations, safety, emerging technologies, and regulatory pathway for New Drug Application (NDA) submission, aligning with the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), FDA regulations, and International Council for Harmonisation (ICH) guidelines. Recommendations emphasize early FDA engagement, robust pharmacovigilance, and equitable access to optimize therapeutic impact.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "Kumari, Piyanka",
            "affiliation": "Northeastern University"
          },
          {
            "name": "Pirouzi, Peivand",
            "affiliation": "Northeastern University"
          }
        ],
        "resource_type": {
          "title": "Publication",
          "type": "publication"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "relations": {
          "version": [
            {
              "index": 0,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "16574280"
              }
            }
          ]
        }
      },
      "title": "Perspectives and Insights on Anti-Dementia Drugs (N06): From Development to New Drug Application (NDA) development for FDA",
      "links": {
        "self": "https://zenodo.org/api/records/16574281",
        "self_html": "https://zenodo.org/records/16574281",
        "preview_html": "https://zenodo.org/records/16574281?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.16574281",
        "self_doi": "https://doi.org/10.5281/zenodo.16574281",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16574281",
        "reserve_doi": "https://zenodo.org/api/records/16574281/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/16574280",
        "parent_html": "https://zenodo.org/records/16574280",
        "parent_doi": "https://doi.org/10.5281/zenodo.16574280",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16574280",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16574281/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16574281/sequence/default",
        "files": "https://zenodo.org/api/records/16574281/files",
        "media_files": "https://zenodo.org/api/records/16574281/media-files",
        "thumbnails": {
          "10": "https://zenodo.org/api/iiif/record:16574281:Anti-Dementia%20Drugs%20%20-%20Crown%20College%20of%20Canada.pdf/full/%5E10,/0/default.jpg",
          "50": "https://zenodo.org/api/iiif/record:16574281:Anti-Dementia%20Drugs%20%20-%20Crown%20College%20of%20Canada.pdf/full/%5E50,/0/default.jpg",
          "100": "https://zenodo.org/api/iiif/record:16574281:Anti-Dementia%20Drugs%20%20-%20Crown%20College%20of%20Canada.pdf/full/%5E100,/0/default.jpg",
          "250": "https://zenodo.org/api/iiif/record:16574281:Anti-Dementia%20Drugs%20%20-%20Crown%20College%20of%20Canada.pdf/full/%5E250,/0/default.jpg",
          "750": "https://zenodo.org/api/iiif/record:16574281:Anti-Dementia%20Drugs%20%20-%20Crown%20College%20of%20Canada.pdf/full/%5E750,/0/default.jpg",
          "1200": "https://zenodo.org/api/iiif/record:16574281:Anti-Dementia%20Drugs%20%20-%20Crown%20College%20of%20Canada.pdf/full/%5E1200,/0/default.jpg"
        },
        "archive": "https://zenodo.org/api/records/16574281/files-archive",
        "archive_media": "https://zenodo.org/api/records/16574281/media-files-archive",
        "latest": "https://zenodo.org/api/records/16574281/versions/latest",
        "latest_html": "https://zenodo.org/records/16574281/latest",
        "versions": "https://zenodo.org/api/records/16574281/versions",
        "draft": "https://zenodo.org/api/records/16574281/draft",
        "access_links": "https://zenodo.org/api/records/16574281/access/links",
        "access_grants": "https://zenodo.org/api/records/16574281/access/grants",
        "access_users": "https://zenodo.org/api/records/16574281/access/users",
        "access_request": "https://zenodo.org/api/records/16574281/access/request",
        "access": "https://zenodo.org/api/records/16574281/access",
        "communities": "https://zenodo.org/api/records/16574281/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16574281/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16574281/requests"
      },
      "updated": "2025-07-29T15:18:01.892872+00:00",
      "recid": "16574281",
      "revision": 8,
      "files": [
        {
          "id": "031e5a5f-2730-4bad-9482-2502ca0c7302",
          "key": "Anti-Dementia Drugs  - Crown College of Canada.pdf",
          "size": 444234,
          "checksum": "md5:7db342ef977977533c796deaad41704e",
          "links": {
            "self": "https://zenodo.org/api/records/16574281/files/Anti-Dementia Drugs  - Crown College of Canada.pdf/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "1228454"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 4,
        "unique_downloads": 2,
        "views": 4,
        "unique_views": 2,
        "version_downloads": 4,
        "version_unique_downloads": 2,
        "version_unique_views": 2,
        "version_views": 4
      },
      "state": "done",
      "submitted": true
    },
    {
      "created": "2025-07-25T14:35:52.668501+00:00",
      "modified": "2025-07-25T14:35:52.815087+00:00",
      "id": 16421590,
      "conceptrecid": "15556734",
      "doi": "10.5281/zenodo.16421590",
      "conceptdoi": "10.5281/zenodo.15556734",
      "doi_url": "https://doi.org/10.5281/zenodo.16421590",
      "metadata": {
        "title": "github.com/DOH-HNH0303/public_health_bioinformatics_waphl/Freyja_FASTQ_PHB",
        "doi": "10.5281/zenodo.16421590",
        "publication_date": "2023-09-05",
        "description": "<h1>Public Health Bioinformatics (PHB) - WAPHL</h1>\n<p>Bioinformatics workflows for characterization, epidemiology and sharing of pathogen genomes. This is the Washington State Department of Health Public Health Lab fork of the Public Health Bioinformatics repository created by Theiagen.</p>\n<p><strong>More information about the steps undertaken in these workflows is available on the <a href=\"https://github.com/DOH-HNH0303/public_health_bioinformatics_waphl/wiki\">Wiki</a> for this repository for all pipelines not containing WAPHL in the workflow filename or via the <a href=\"https://theiagen.notion.site/Theiagen-Public-Health-Resources-a4bd134b0c5c4fe39870e21029a30566\">Theiagen Public Resources Documentation</a> for all other pipelines.</strong></p>\n<p>Support for running these workflows can be sought by raising a <a href=\"https://github.com/theiagen/public_health_bioinformatics/issues/new\">GitHub issue</a> or by contacting Theiagen at support@theiagen.com. For workflows ending with WAPHL please contact <a href=\"mailto:holly.halstead@doh.wa.gov\">Holly Halstead</a>.</p>\n<p>These workflows are written in <a href=\"https://github.com/openwdl/wdl\">WDL</a>, a language for specifying data processing workflows with a human-readable and writeable syntax. They have been developed by <a href=\"https://theiagen.com/\">Theiagen Genomics</a> and WAPHL to primarily run on the <a href=\"https://terra.bio/\">Terra.bio</a> platform.</p>\n<h3>Contributors &amp; Influence</h3>\n<ul>\n<li>Based on collaborative work with Andrew Lang, PhD &amp; his <a href=\"https://github.com/AndrewLangvt/genomic_analyses\">Genomic Analysis WDL workflows</a></li>\n<li>Workflows and task development influenced by The Broad's <a href=\"https://github.com/broadinstitute/viral-pipelines\">Viral Pipes</a></li>\n<li>TheiaCoV workflows for viral genomic characterization influenced by UPHL's <a href=\"https://github.com/UPHL-BioNGS/Cecret\">Cecret</a> &amp; StaPH-B's <a href=\"https://staph-b.github.io/staphb_toolkit/workflow_docs/monroe/\">Monroe</a></li>\n<li>TheiaProk workflows for bacterial genomic characterization influenced by Robert Petit's <a href=\"https://github.com/bactopia/bactopia\">bactopia</a></li>\n<li>The PHB workflow user community. To provide feedback to pipeline's not ending in WAPHL, please visit the original repository for <a href=\"https://github.com/theiagen/public_health_bioinformatics\">Public Health Bioinformatics</a>.</li>\n<li>Tasks using in WAPHL pipelines are highly derived from tasks in the original <a href=\"https://github.com/theiagen/public_health_bioinformatics\">Public Health Bioinformatics</a> repository created by Theiagen</li>\n<li>RECAPP is based around the use of Nick Croucher's <a href=\"https://github.com/nickjcroucher/gubbins\">Gubbins</a></li>\n</ul>\n<p><em>\"DISCLAIMER: This test was adopted, and its performance characteristics determined by the WA PHL. It has not been approved by the FDA. Results are for infection control and epidemiological purposes and should not be used as the sole means for clinical diagnosis or patient management.\"</em></p>\n<h3>Citation</h3>\n<p>Please cite this paper if publishing work using any pipelines <strong>not containing WAPHL in the workflow filename</strong>:</p>\n<p>Libuit, Kevin G., Emma L. Doughty, James R. Otieno, Frank Ambrosio, Curtis J. Kapsak, Emily A. Smith, Sage M. Wright, et al. 2023. \"Accelerating Bioinformatics Implementation in Public Health.\" Microbial Genomics 9 (7). https://doi.org/10.1099/mgen.0.001051.</p>\n<p>Alternatively, please cite this paper if using the TheiaEuk workflow:</p>\n<p>Ambrosio, Frank, Michelle Scribner, Sage Wright, James Otieno, Emma Doughty, Andrew Gorzalski, Danielle Siao, et al. 2023. \"TheiaEuk: A Species-Agnostic Bioinformatics Workflow for Fungal Genomic Characterization.\" Frontiers in Public Health 11. https://doi.org/10.3389/fpubh.2023.1198213.</p>",
        "access_right": "open",
        "creators": [
          {
            "name": "DOH-HNH0303",
            "affiliation": null
          }
        ],
        "related_identifiers": [
          {
            "identifier": "https://dockstore.org/aliases/workflow-versions/10.5281-zenodo.16421590",
            "relation": "isIdenticalTo",
            "scheme": "url"
          },
          {
            "identifier": "https://dockstore.org/workflows/github.com/DOH-HNH0303/public_health_bioinformatics_waphl/Freyja_FASTQ_PHB:v1.0.2",
            "relation": "isIdenticalTo",
            "scheme": "url"
          },
          {
            "identifier": "https://dockstore.org/api/ga4gh/trs/v2/tools/%23workflow%2Fgithub.com%2FDOH-HNH0303%2Fpublic_health_bioinformatics_waphl%2FFreyja_FASTQ_PHB/versions/v1.0.2/PLAIN-WDL/descriptor/wf_freyja_fastq.wdl",
            "relation": "isIdenticalTo",
            "scheme": "url"
          }
        ],
        "version": "v1.0.2",
        "resource_type": {
          "title": "Software",
          "type": "software"
        },
        "license": {
          "id": "cc-by-4.0"
        },
        "communities": [
          {
            "id": "f312c6b6-0dd6-4fb2-a224-7c4960394ac1"
          },
          {
            "id": "dockstore"
          }
        ],
        "relations": {
          "version": [
            {
              "index": 3,
              "is_last": true,
              "parent": {
                "pid_type": "recid",
                "pid_value": "15556734"
              }
            }
          ]
        }
      },
      "title": "github.com/DOH-HNH0303/public_health_bioinformatics_waphl/Freyja_FASTQ_PHB",
      "links": {
        "self": "https://zenodo.org/api/records/16421590",
        "self_html": "https://zenodo.org/records/16421590",
        "preview_html": "https://zenodo.org/records/16421590?preview=1",
        "doi": "https://doi.org/10.5281/zenodo.16421590",
        "self_doi": "https://doi.org/10.5281/zenodo.16421590",
        "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.16421590",
        "reserve_doi": "https://zenodo.org/api/records/16421590/draft/pids/doi",
        "parent": "https://zenodo.org/api/records/15556734",
        "parent_html": "https://zenodo.org/records/15556734",
        "parent_doi": "https://doi.org/10.5281/zenodo.15556734",
        "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.15556734",
        "self_iiif_manifest": "https://zenodo.org/api/iiif/record:16421590/manifest",
        "self_iiif_sequence": "https://zenodo.org/api/iiif/record:16421590/sequence/default",
        "files": "https://zenodo.org/api/records/16421590/files",
        "media_files": "https://zenodo.org/api/records/16421590/media-files",
        "archive": "https://zenodo.org/api/records/16421590/files-archive",
        "archive_media": "https://zenodo.org/api/records/16421590/media-files-archive",
        "latest": "https://zenodo.org/api/records/16421590/versions/latest",
        "latest_html": "https://zenodo.org/records/16421590/latest",
        "versions": "https://zenodo.org/api/records/16421590/versions",
        "draft": "https://zenodo.org/api/records/16421590/draft",
        "access_links": "https://zenodo.org/api/records/16421590/access/links",
        "access_grants": "https://zenodo.org/api/records/16421590/access/grants",
        "access_users": "https://zenodo.org/api/records/16421590/access/users",
        "access_request": "https://zenodo.org/api/records/16421590/access/request",
        "access": "https://zenodo.org/api/records/16421590/access",
        "communities": "https://zenodo.org/api/records/16421590/communities",
        "communities-suggestions": "https://zenodo.org/api/records/16421590/communities-suggestions",
        "requests": "https://zenodo.org/api/records/16421590/requests"
      },
      "updated": "2025-07-25T14:35:52.815087+00:00",
      "recid": "16421590",
      "revision": 4,
      "files": [
        {
          "id": "5e734c7c-f82a-4408-b978-3177bda936ad",
          "key": "github.com-DOH-HNH0303-public_health_bioinformatics_waphl-Freyja_FASTQ_PHB_v1.0.2.zip",
          "size": 18539,
          "checksum": "md5:e9a1a9c8031e458e3732db15e28d78d0",
          "links": {
            "self": "https://zenodo.org/api/records/16421590/files/github.com-DOH-HNH0303-public_health_bioinformatics_waphl-Freyja_FASTQ_PHB_v1.0.2.zip/content"
          }
        }
      ],
      "swh": {},
      "owners": [
        {
          "id": "76183"
        }
      ],
      "status": "published",
      "stats": {
        "downloads": 28,
        "unique_downloads": 27,
        "views": 37,
        "unique_views": 37,
        "version_downloads": 0,
        "version_unique_downloads": 0,
        "version_unique_views": 2,
        "version_views": 2
      },
      "state": "done",
      "submitted": true
    }
  ]
}